BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20553278)

  • 1. Apixaban in acute coronary syndromes.
    Karthikeyan G; Eikelboom JW
    Cardiovasc Ther; 2011 Oct; 29(5):285-90. PubMed ID: 20553278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of apixaban : where do we stand in 2013?
    de Souza Brito F; Lopes RD; Alexander JH
    Expert Opin Drug Saf; 2013 Jul; 12(4):559-67. PubMed ID: 23662974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban: an oral direct factor-xa inhibitor.
    Jiménez D; Yusen RD; Ramacciotti E
    Adv Ther; 2012 Mar; 29(3):187-201. PubMed ID: 22354465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of apixaban for venous and arterial thromboembolic disease.
    Prom R; Spinler SA
    Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban for the prevention of stroke in atrial fibrillation.
    Littrell R; Flaker G
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban in other situations?
    Prescrire Int; 2012 Sep; 21(130):203. PubMed ID: 23016248
    [No Abstract]   [Full Text] [Related]  

  • 10. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
    Lassen MR; Gallus A; Raskob GE; Pineo G; Chen D; Ramirez LM;
    N Engl J Med; 2010 Dec; 363(26):2487-98. PubMed ID: 21175312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban, an oral, direct inhibitor of activated Factor Xa.
    Shantsila E; Lip GY
    Curr Opin Investig Drugs; 2008 Sep; 9(9):1020-33. PubMed ID: 18729009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice].
    MMW Fortschr Med; 2013 Sep; 155(16):62-3. PubMed ID: 24279159
    [No Abstract]   [Full Text] [Related]  

  • 13. A new generation of oral direct anticoagulants.
    Soff GA
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):569-74. PubMed ID: 22345595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
    Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
    Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Kar S; Bhatt DL
    Coron Artery Dis; 2012 Sep; 23(6):380-90. PubMed ID: 22728913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation?
    Strain J; Templeton K
    S D Med; 2013 Jan; 66(1):20-1. PubMed ID: 23342716
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
    Martin MT; Nutescu EA
    Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
    Huang J; Cao Y; Liao C; Wu L; Gao F
    Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.